Skip to content

ARDX

Ardelyx, Inc.

NASDAQ · USHealthcareBiotechnology
$5.09-2.12%

Price as of Jul 20, 2026

ARDX growth

Ardelyx, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue
+18.2%
EBITDA
+9.6%
EBIT
+5.6%
EPS
-5.0%
Free cash flow
+23.0%
Operating cash flow
+23.7%

Forward estimates

Revenue
+46.1%
EBITDA
EPS
+161.8%

Three-year CAGR

Revenue
+98.4%
EBITDA
-74.6%
EBIT
-46.6%
Net income
-57.4%
EPS
-52.9%
Free cash flow
+4.0%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.